A citation-based method for searching scientific literature

Viktoria F Koehler, Pia Adam, Karin Frank-Raue, Friedhelm Raue, Elke Berg, Eva Hoster, Stephanie Allelein, Matthias Schott, Matthias Kroiss, Christine Spitzweg. Thyroid 2021
Times Cited: 21







List of co-cited articles
165 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Samuel A Wells, Sylvia L Asa, Henning Dralle, Rossella Elisei, Douglas B Evans, Robert F Gagel, Nancy Lee, Andreas Machens, Jeffrey F Moley, Furio Pacini,[...]. Thyroid 2015
960
52

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
865
52

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
192
47

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
673
42

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
M Schlumberger, R Elisei, S Müller, P Schöffski, M Brose, M Shah, L Licitra, J Krajewska, M C Kreissl, B Niederle,[...]. Ann Oncol 2017
90
38

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
S Filetti, C Durante, D Hartl, S Leboulleux, L D Locati, K Newbold, M G Papotti, A Berruti. Ann Oncol 2019
241
33

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
33

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
974
28

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Vivek Subbiah, Mimi I Hu, Lori J Wirth, Martin Schuler, Aaron S Mansfield, Giuseppe Curigliano, Marcia S Brose, Viola W Zhu, Sophie Leboulleux, Daniel W Bowles,[...]. Lancet Diabetes Endocrinol 2021
65
28

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Martin Schlumberger, Barbara Jarzab, Maria E Cabanillas, Bruce Robinson, Furio Pacini, Douglas W Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G Martins,[...]. Clin Cancer Res 2016
137
23

New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations.
Cristina Romei, Francesca Casella, Alessia Tacito, Valeria Bottici, Laura Valerio, David Viola, Virginia Cappagli, Antonio Matrone, Raffaele Ciampi, Paolo Piaggi,[...]. J Med Genet 2016
35
23

Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
Lucieli Ceolin, Marta Amaro da Silveira Duval, Antônio Felippe Benini, Carla Vaz Ferreira, Ana Luiza Maia. Endocr Relat Cancer 2019
43
23

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.
Michael C Kreissl, Lars Bastholt, Rossella Elisei, Robert Haddad, Ole Hauch, Barbara Jarząb, Bruce Robinson, Raffaella Colzani, Meredith Foster, Richard Weiss,[...]. J Clin Oncol 2020
17
29

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
371
23

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
V Subbiah, T Shen, S S Terzyan, X Liu, X Hu, K P Patel, M Hu, M Cabanillas, A Behrang, F Meric-Bernstam,[...]. Ann Oncol 2021
60
23

Selective RET kinase inhibition for patients with RET-altered cancers.
V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault,[...]. Ann Oncol 2018
197
23

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
858
23

A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura,[...]. Future Oncol 2019
73
19

Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.
Anne Laure Giraudet, Abir Al Ghulzan, Anne Aupérin, Sophie Leboulleux, Ahmed Chehboun, Frédéric Troalen, Clarisse Dromain, Jean Lumbroso, Eric Baudin, Martin Schlumberger. Eur J Endocrinol 2008
147
19

Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.
Laura Valerio, Valeria Bottici, Antonio Matrone, Paolo Piaggi, David Viola, Virginia Cappagli, Laura Agate, Eleonora Molinaro, Raffaele Ciampi, Alessia Tacito,[...]. Endocr Relat Cancer 2020
10
40

Biologic and Clinical Perspectives on Thyroid Cancer.
James A Fagin, Samuel A Wells. N Engl J Med 2016
421
19

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Stephen R Wedge, Donald J Ogilvie, Michael Dukes, Jane Kendrew, Rosemary Chester, Janet A Jackson, Sarah J Boffey, Paula J Valentine, Jon O Curwen, Helen L Musgrove,[...]. Cancer Res 2002
724
19

Drug resistance profiles of mutations in the RET kinase domain.
Xuan Liu, Tao Shen, Blaine H M Mooers, Frank Hilberg, Jie Wu. Br J Pharmacol 2018
40
19

Management of advanced medullary thyroid cancer.
Julien Hadoux, Furio Pacini, R Michael Tuttle, Martin Schlumberger. Lancet Diabetes Endocrinol 2016
62
19

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
Dapeng Li, Yihebali Chi, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng,[...]. Clin Cancer Res 2021
16
25

Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
Mijin Kim, Jee Hee Yoon, Jonghwa Ahn, Min Ji Jeon, Hee Kyung Kim, Dong Jun Lim, Ho-Cheol Kang, In Joo Kim, Young Kee Shong, Tae Yong Kim,[...]. Endocrinol Metab (Seoul) 2020
8
50

Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
Helton Estrela Ramos, Fabio Hecht, Amandine Berdelou, Isabelle Borget, Sophie Leboulleux, Eric Baudin, Martin Schlumberger. Endocrine 2021
10
40

Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years.
Reese W Randle, Courtney J Balentine, Glen E Leverson, Jeffrey A Havlena, Rebecca S Sippel, David F Schneider, Susan C Pitt. Surgery 2017
94
19

Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing.
Raffaele Ciampi, Cristina Romei, Teresa Ramone, Alessandro Prete, Alessia Tacito, Virginia Cappagli, Valeria Bottici, David Viola, Liborio Torregrossa, Clara Ugolini,[...]. iScience 2019
55
19

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Elaine T Lam, Matthew D Ringel, Richard T Kloos, Thomas W Prior, Michael V Knopp, Jiachao Liang, Steffen Sammet, Nathan C Hall, Paul E Wakely, Vasyl V Vasko,[...]. J Clin Oncol 2010
276
19

Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.
Hyeyeun Lim, Susan S Devesa, Julie A Sosa, David Check, Cari M Kitahara. JAMA 2017
931
19

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Steven I Sherman, Douglas O Clary, Rossella Elisei, Martin J Schlumberger, Ezra E W Cohen, Patrick Schöffski, Lori J Wirth, Milan Mangeshkar, Dana T Aftab, Marcia S Brose. Cancer 2016
57
19

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, Kevin Ebata, Brian B Tuch, Satoshi Yoda, Justin F Gainor, Lecia V Sequist,[...]. J Thorac Oncol 2020
99
19

Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma.
Eric J Kuo, Shonan Sho, Ning Li, Kyle A Zanocco, Michael W Yeh, Masha J Livhits. JAMA Surg 2018
35
14

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Martin J Schlumberger, Rossella Elisei, Lars Bastholt, Lori J Wirth, Renato G Martins, Laura D Locati, Barbara Jarzab, Furio Pacini, Chantal Daumerie, Jean-Pierre Droz,[...]. J Clin Oncol 2009
257
14

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
14

A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
Nigel Fleeman, Rachel Houten, Marty Chaplin, Sophie Beale, Angela Boland, Yenal Dundar, Janette Greenhalgh, Rui Duarte, Aditya Shenoy. BMC Cancer 2019
24
14

New drugs for medullary thyroid cancer: new promises?
Christine Spitzweg, John C Morris, Keith C Bible. Endocr Relat Cancer 2016
16
18

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Francesca Carlomagno, Donata Vitagliano, Teresa Guida, Fortunato Ciardiello, Giampaolo Tortora, Giancarlo Vecchio, Anderson J Ryan, Gabriella Fontanini, Alfredo Fusco, Massimo Santoro. Cancer Res 2002
481
14

Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
Samuel A Wells, Furio Pacini, Bruce G Robinson, Massimo Santoro. J Clin Endocrinol Metab 2013
183
14

Management of Medullary Thyroid Cancer.
David Viola, Rossella Elisei. Endocrinol Metab Clin North Am 2019
30
14

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
L M Mulligan, J B Kwok, C S Healey, M J Elsdon, C Eng, E Gardner, D R Love, S E Mole, J K Moore, L Papi. Nature 1993
14

RET mutation and increased angiogenesis in medullary thyroid carcinomas.
Antonella Verrienti, Giovanni Tallini, Chiara Colato, Amélie Boichard, Saula Checquolo, Valeria Pecce, Marialuisa Sponziello, Francesca Rosignolo, Dario de Biase, Kerry Rhoden,[...]. Endocr Relat Cancer 2016
16
18

Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis.
Johannes A A Meijer, Saskia le Cessie, Wilbert B van den Hout, Job Kievit, Johannes W Schoones, Johannes A Romijn, Johannes W A Smit. Clin Endocrinol (Oxf) 2010
95
14

Thyroid cancer.
Maria E Cabanillas, David G McFadden, Cosimo Durante. Lancet 2016
617
14

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
C Belli, F Penault-Llorca, M Ladanyi, N Normanno, J-Y Scoazec, L Lacroix, J S Reis-Filho, V Subbiah, J F Gainor, V Endris,[...]. Ann Oncol 2021
32
14


Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
Julien Hadoux, Martin Schlumberger. Best Pract Res Clin Endocrinol Metab 2017
22
14

Benefits and Limitations of TKIs in Patients with Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis.
Zoe A Efstathiadou, Charalambos Tsentidis, Alexandra Bargiota, Vasiliki Daraki, Kalliopi Kotsa, Georgia Ntali, Labrini Papanastasiou, Stelios Tigas, Konstantinos Toulis, Kalliopi Pazaitou-Panayiotou,[...]. Eur Thyroid J 2021
6
50

Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.
Fabienne Iten, Beat Müller, Christian Schindler, Christoph Rochlitz, Daniel Oertli, Helmut R Mäcke, Jan Müller-Brand, Martin A Walter. Clin Cancer Res 2007
96
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.